Intérêt d’un dépistage systématique du phéochromocytome chez les patients porteurs d’une neurofibromatose de type 1
P. Combemale(Centre Léon Bérard), Françoise Borson‐Chazot(Hospices Civils de Lyon), A.-L. Girodet, C. Houzard(Hôpital Lyon Sud), Thomas Mognetti(Centre de Recherche en Cancérologie de Lyon), S. Pinson(Hôpital Edouard Herriot), J.C. Lifante(Hospices Civils de Lyon), L. Képénékian(Hospices Civils de Lyon)
Cited by 0
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study
|Annals of Oncology|2015|257
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192